RemeGen Co., Ltd. (FRA:REG)

Market Cap	6.23B +320.2%
Revenue (ttm)	266.71M +46.3%
Net Income	-113.45M
EPS	-0.21
Shares Out	n/a
PE Ratio	n/a
Forward PE	145.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	210
Open	8.85
Previous Close	8.80
Day's Range	8.85 - 8.85
52-Week Range	7.90 - 11.20
Beta	n/a
RSI	53.78
Earnings Date	Mar 28, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 3,070
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: REG

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.54% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.84% less than in 2023.

Financial numbers in CNY